Loxo Oncology was a biopharmaceutical company focused on developing precision oncology medicines targeting cancers driven by specific genetic abnormalities. Its pipeline included larotrectinib (VITRAKVI), the first FDA-approved tumor-agnostic TRK inhibitor. The company was acquired by Eli Lilly in February 2019 for approximately $8 billion.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2019
Aug 2014
May 2014
Oct 2013
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
